The post SEC Cryptocurrency Enforcement Actions Drop by 60% in 2025 appeared on BitcoinEthereumNews.com. Key Points: SEC actions fell 60% in 2025 under new leadershipThe post SEC Cryptocurrency Enforcement Actions Drop by 60% in 2025 appeared on BitcoinEthereumNews.com. Key Points: SEC actions fell 60% in 2025 under new leadership

SEC Cryptocurrency Enforcement Actions Drop by 60% in 2025

Key Points:
  • SEC actions fell 60% in 2025 under new leadership.
  • Shift from broad registration to specific fraud cases.
  • Monetary penalties reduced significantly from previous year.

In 2025, under the leadership of Chairman Paul Atkins, the U.S. Securities and Exchange Commission drastically reduced its cryptocurrency-related enforcement actions, marking a significant policy shift.

This change highlights a regulatory pivot towards addressing specific investor harm, potentially impacting future digital asset compliance strategies significantly.

Fraud-Focused Strategy Cuts SEC Actions by 60% in 2025

Under Paul Atkins, the SEC’s approach in 2025 shows a strategic reduction in enforcement actions. New leadership placed emphasis on addressing fraud and investor harm, resulting in only 13 crypto-related cases that primarily focused on these aspects. The SEC’s broader shift away from large-scale registration enforcement is evident, with dismissals of noteworthy cases involving major platforms like Coinbase and Binance, marking significant precedents in regulatory actions. Such decisions suggest a strategic move towards rule-making, significantly altering the landscape and reducing fines by $142 million compared to the previous year.

Market reactions to these regulatory shifts appear mixed. While some platforms welcomed their case dismissals, the absence of direct statements from key figures such as Paul Atkins indicates a cautious stance. Commissioners like Hester Peirce, however, have driven the creation of a Crypto Task Force, reinforcing efforts to create a clear regulatory framework.

2025 SEC Shift Lowers Fines, Market Impact Analyzed

Did you know? The SEC’s 2025 shift to focus primarily on fraud cases marked the lowest level of enforcement actions since 2017, having initiated 33 actions the previous year. This change suggests a departure from the “regulation-by-enforcement” strategies of earlier years.

As of January 23, 2026, Ethereum (ETH) is trading at $2,960.55 with a market cap of $357.32 billion. CoinMarketCap reports a 24-hour volume of $21.04 billion, a 39.95% decrease. Ethereum’s 90-day price has declined by 24.72%, indicating significant market volatility and challenges amid evolving regulatory landscapes.

Ethereum(ETH), daily chart, screenshot on CoinMarketCap at 02:08 UTC on January 23, 2026. Source: CoinMarketCap

Insights from Coincu research team indicate that Atkins’ leadership may drive regulatory structures based on comprehensive frameworks rather than enforcement-led approaches, aligning with broader market stability trends observed historically. Regulatory adjustments may continue into 2026, with potential impacts on market dynamics.

Source: https://coincu.com/news/sec-crypto-actions-decrease-2025/

Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen [email protected] ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Paylaş
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Paylaş
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Paylaş
BitcoinEthereumNews2025/09/18 05:26